Creo Medical Group (LON:CREO) Shares Climb 1.8% – Time to Buy?

Creo Medical Group PLC (LON:CREO) shares traded up 1.8% on Friday. The company traded as high as GBX 12.47 and last traded at GBX 12.47. Approximately 126,580 shares changed hands during trading, a decline of 83% from the average daily volume of 748,931 shares. The stock had previously closed at GBX 12.25.

Analyst Upgrades and Downgrades

Separately, Shore Capital Group restated a “house stock” rating and set a GBX 40 price objective on shares of Creo Medical Group in a research report on Thursday, July 23rd.

Creo Medical Group Stock Up 1.8%

The company has a quick ratio of 2.19, a current ratio of 3.22 and a debt-to-equity ratio of 8.20. The company has a 50 day simple moving average of GBX 12.84 and a two-hundred day simple moving average of GBX 12.91. The company has a market capitalization of £60.57 million, a P/E ratio of 12.47 and a beta of 1.56.

Insider Buying and Selling

In related news, insider Richard John Rees purchased 6,250 shares of the firm’s stock in a transaction that occurred on Wednesday, July 1st. The shares were bought at an average price of GBX 14 per share, for a total transaction of £875. Also, insider Craig Jonathan Gulliford purchased 6,250 shares of the stock in a transaction that occurred on Wednesday, July 1st. The stock was bought at an average price of GBX 14 per share, with a total value of £875. 7.00% of the stock is currently owned by insiders.

About Creo Medical Group

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company’s vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes.